Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sonic HealthcareSTU:SAB -2.19%70 EV-to-OCF is 11.30 as of Aug. 27, 2026, which is 32% below its 10-year median of 16.54. GuruFocus rates STU:SAB with a GF Score™ of 70/100 and a GF Value™ of €18.85 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Sonic Healthcare ranks worse than 60.85% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sonic Healthcare's Enterprise Value is €9,362 Mil.
Sonic Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €828 Mil. Therefore, Sonic Healthcare's EV-to-OCF for today is 11.30.
The historical rank and industry rank for Sonic Healthcare's EV-to-OCF or its related term are showing as below:
STU:SAB'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.02 Med: 16.54 Max: 23.22
Current: 11.34
During the past 13 years, the highest EV-to-OCF of Sonic Healthcare was 23.22. The lowest was 8.02. And the median was 16.54.
STU:SAB's EV-to-OCF is ranked worse than 60.85% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 6
vs STU:SAB: 11.34
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sonic Healthcare's PE Ratio (TTM) for today is calculated as:
Sonic Healthcare's share price for today is €12.34.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sonic Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.727.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sonic Healthcare EV-to-OCF Related Terms
Sonic Healthcare EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sonic Healthcare's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Sonic Healthcare's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonic Healthcare EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sonic Healthcare's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sonic Healthcare's EV-to-OCF falls into.
Sonic Healthcare's current Enterprise Value is €9,362 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sonic Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €828 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonic Healthcare (STU:SAB) has a EV-to-OCF of 11.30 as of Aug. 27, 2026. This is 32% below median its historical median of 16.54. Over the past decade, Sonic Healthcare's EV-to-OCF has ranged from 8.02 to 23.22. According to the industry distribution chart, Sonic Healthcare ranks #129 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 60.8%.
Is Sonic Healthcare's EV-to-OCF too high?
Sonic Healthcare's current EV-to-OCF of 11.30 is 32% below median its 10-year median of 16.54. Over the past 10 years, this metric has ranged from a low of 8.02 to a high of 23.22. The Medical Diagnostics & Research industry median EV-to-OCF is 6.00. Sonic Healthcare's value of 11.30 is 88.3% above this industry median. Based on the distribution chart, Sonic Healthcare ranks #129 out of 212 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Sonic Healthcare has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonic Healthcare's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sonic Healthcare ranks #129 out of 212 companies for EV-to-OCF. This places Sonic Healthcare in the lower half of its industry. The industry median EV-to-OCF is 6.00. Sonic Healthcare's value of 11.30 is 88.3% above this benchmark. Historically, Sonic Healthcare's own EV-to-OCF has ranged from 8.02 to 23.22 over the past decade. While the company's 10-year median is 16.54 vs. the industry median of 6.00, Sonic Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.00, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sonic Healthcare's current EV-to-OCF of 11.30 is 88.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonic Healthcare's current EV-to-OCF is 11.30, which is 32% below median its own 10-year median of 16.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonic Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sonic Healthcare (STU:SAB) is currently considered Significantly Undervalued. The stock's GF Value™ is €18.85, compared to a current price of €12.34 — trading 34.5% below its estimated fair value. The current EV-to-OCF is 11.30, which is 32% below median its 10-year median of 16.54 and 88.3% above the Medical Diagnostics & Research industry median of 6.00. Sonic Healthcare's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sonic Healthcare (STU:SAB), the current EV-to-OCF is 11.30 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonic Healthcare (STU:SAB) Overvalued in 2026?
Based on GuruFocus' analysis, Sonic Healthcare stock appears to be undervalued.
The current stock price of €12.34 is trading 34.5% below its estimated GF Value™ of €18.85.
GuruFocus considers Sonic Healthcare to be Significantly Undervalued.
Key valuation signals for STU:SAB:
EV-to-OCF: 11.30 (32% below median its 10-year median of 16.54)
GF Value™: €18.85 vs. price of €12.34 (34.5% below fair value)
Industry Position: 88.3% above the Medical Diagnostics & Research median (#129 of 212)
No single metric tells the full story. See the STU:SAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe.
70GF Score
Get the complete analysis for STU:SAB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SAB has been successfully added to your 
